Navigation Links
Men's Health Policy Center Hosts Petition to Protest Government Barrier to Prostate Cancer Medications
Date:3/27/2008

WASHINGTON, March 27 /PRNewswire-USNewswire/ -- The Men's Health Policy Center, a new resource center affiliated with the Men's Health Network (MHN), announced today that they are hosting an online petition urging Congress to end a Centers for Medicare and Medicaid Services (CMS) practice that unfairly restricts prostate cancer patients' access to drug therapies.

"This petition allows people who are impacted by prostate cancer to raise their united voices and let their Congressional leaders know that they are opposed to this policy," said Theresa Morrow, Director of Marketing and External Relations for MHN. "In order to ensure the best quality of life, prostate cancer patients should be treated according to the most effective treatment for them as determined by their physician and not according to what is cheapest."

The policy, known as "least costly alternative" (LCA), allows CMS to deny the additional payment for certain cancer therapies based solely on cost with no consideration for the clinical recommendations given by a patient's own physician. Groups such as the National Prostate Cancer Coalition, the Prostate Health Education Network, and Us TOO have also urged Congress and the Administration to drop the LCA policy for prostate cancer therapies.

"As a prostate cancer survivor, I struggle daily with the emotional and financial ramifications of my illness, and the last thing I need to worry about is how to pay for the care that's best for me. I believe all men should have access to the full range of treatments available without the federal government coming in between my doctor and me," said William Palos, a survivor from Illinois. "With nearly 200,000 men diagnosed with this disease each year, I don't think we should be singled out and forced to settle for substandard care."

Prostate cancer is the most frequently diagnosed cancer among men and is the second leading cause of cancer death among men. This cancer disproportionately affects the elderly and African-American men. According to the American Cancer Society, nearly 5,700 African-American men die from prostate cancer each year with a death rate that is 2.4 times higher than white men.

The petition urges Congress to demand the reversal of the use of LCA for prostate cancer drug therapies to ensure patients have access to vital drug treatments.

To view the petition, go to the Men's Health Policy Center website at: http://www.menshealthpolicy.com/advocacy/lcaPetition.php

Men's Health Policy Center (MHPC) is a public policy resource center, affiliated with Men's Health Network, that enables readers to better understand complex issues and advocate for the health and well being of men and their families.

Our goal is to improve the lives of every person by providing him or her with the tools necessary to make change. MHPC empowers individuals by offering strategies and tools that are helpful in advocating for better men's health. On federal and state levels of government, we offer information about key legislation and government initiatives. MHPC provides coverage of the legislative process, and the impact it will have on men and their families. As a part of that process, MHPC will periodically host letter-writing campaigns for individuals to voice their concern about key issues.


'/>"/>
SOURCE Men's Health Network
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Siemens Installs First High-Definition PET-CT
2. Siemens Urological Systems Tap U.S. Market
3. Siemens Consortium to Construct Particle Therapy Center at the University Clinic of Schleswig-Holstein
4. Siemens Showcases Latest Ultrasound Technologies at AIUM 2008
5. Siemens Introduces New Dual Energy Applications to SOMATOM Definition
6. VIDEO from Medialink and Siemens: NFL Stars Stress the Importance of a Healthy Heart
7. Siemens Signs New Revenue Cycle Management Customers
8. Trial finds tenofovir gel safe for daily use and most women adhered to study regimens
9. Americans Believe Pettitte had Conversations with Clemens Regarding Both Players Use of HGH
10. Siemens Receives FDA Approval for the VERSANT 440 Molecular System
11. Specimens in BODY WORLDS Exhibitions Stem Primarily from German Body Donation Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... January 16, 2017 , ... Houston ... Center, is currently offering complimentary consultations and financing for orthodontics for a limited ... bite irregularities and learn about their orthodontic options. Walk-in, late-evening, Saturday, and same-day ...
(Date:1/16/2017)... MO (PRWEB) , ... January 16, 2017 , ... St. Louisans are well-aware of the ... , This year’s influenza shot seems to be having no effect on keeping ... at least half of the people around are coughing, sneezing, or sniffling ...
(Date:1/16/2017)... ... , ... San Francisco dentist, Dr. Ben Amini , the founder at ... is capable of taking digital impressions of teeth and gums. Conventional bite impressions have ... restorations , in terms of speed, efficiency and patient comfort. Increasingly, digital impressions are ...
(Date:1/15/2017)... ... 15, 2017 , ... Whole Health Supply, LLC is announcing the release of an updated version ... for purchase. , The 2017 edition has wide jaws that will accommodate nails up ... as well as diabetics. This handle is reinforced for extra strength when pressing down on ...
(Date:1/15/2017)... ... January 15, 2017 , ... The Gravity Vault Indoor Rock Climbing Gym is ... wraps up on the 14,000+ square foot climbing gym, the owners anticipate to open ... in New Jersey and two in New York. With this being its first location ...
Breaking Medicine News(10 mins):
(Date:1/14/2017)... , Jan. 14, 2017  Johnson & Weaver, LLP ... of purchasers of Zimmer Biomet Holdings, Inc. (NYSE: ... through October 31, 2016 (the "Class Period"). Zimmer ... and markets orthopaedic reconstructive products, such as knee and hip ... ...
(Date:1/13/2017)... Eli Lilly and Company (NYSE: ... ) announced today that the U.S. Food and Drug ... new drug application (NDA) for investigational baricitinib, a once-daily ... rheumatoid arthritis (RA). The NDA for baricitinib was submitted ... FDA extended the action date to allow time to ...
(Date:1/13/2017)... New York , January 13, 2017 ... rising prevalence of AIDS will collectively contribute to the demand ... expected to reach a value of US$ 551.0 Mn by ... will remain the most lucrative markets for western blotting, ... lead the market globally. ...
Breaking Medicine Technology: